click enter text
full postview best quarter look
flattish us pipelin certainli look better
report financi result tuesday compani came
bit light revenu beat ep narrow lower
revenu guidanc maintain mid-point previous provid
non-gaap ep guidanc worrisom develop
slowdown ibranc us growth y/i sequenti downsid risk
made us nervou even today print
bodi report full analysi
addit detail us/eu drug compani
cover see recent initi report oct global
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
tuesday open
report result beat consensu ep estim came touch light revenu
narrowed/low revenu guidanc narrow ep guidanc midpoint
futur highlight in-lin brand continu call pipelin say best ever
manag ask overal price environ us sever differ occas
compani said least term polici practic expect
differ like peer big pharma advoc certain chang us healthcar polici
would fairli benign drug industri extens could impact channel
particip includ concept like increas pos discount chang rebat structur
would lower patient out-of-pocket spend view like news front year-
end said outgo ceo ian read last confer call succeed
albert bourla intern promot usual expect bourla alreadi execut
committe deviat much predecessor term effect major chang rule
major structur shift split engag big heavili consid
differ point time mean futur come perform base deliveri
new therapeut pipelin year may great one term growth
schedul lyrica loe model growth also come low level outlook
improv reason recent re-initi peer-perform rate despit
pipelin better
term sale ep exhibit
revenu report sale vs consensu estim
ep report non-gaap ep vs consensu estim
ibranc sale vs consensu estim us growth stall
import cancer product sale vs vs prior sequenti quarter
prevnar sale vs estim consensu growth fuel primarili due
higher govern purchas pediatr indic
narrowed/low financi guidanc exhibit
revenu narrow lower guidanc vs prior
page
ep narrow maintain guidanc vs prior mid-point
pipelin materi new news disclos
revenu decreas ep decreas
revenu estim decreas ep estim chang
depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate stay repres peer averag
price target unchang repres unchang ep estim
gener prepar remark note
think long-term mention need increas new market creation activ
increment cost find offset indirect sg
pfe essenti health busi abl achiev sustain low revenu growth
disavow larg
 ahead adjuv data drive growth metastat diseas continu roll-out metastat
diseas differ geographi
 show non-stat sig os trend impact price access ex-u
rais risk show two on-going adjuv trial describ result
clinic signific even stat sig hit clearli answer question
implic could ex-u perform term risk adjuv trial read out
doesnt see read-across claim chang perspect
one-tim true-up access-bas payment one payer impact revenu
page
 take recent acip meet pneumococc vaccin state acip rel earli
process make determin believ broad recommend continu
vaccin warrant expect decis sometim
 impact gener zytiga gener launch gener dont expect impact
xtandi much partli indic differ
 would consid launch author gener improv access certain us government program
say would unusu move suggest occur
continu say decis busi made end year
well-posit continu growth
continu see good futur growth opportun still challeng us commerci
exclusionari practic better traction government program
 say oper margin biosimilar busi
futur balanc input play describ similar steril inject
busi limit entrant capit cost quantif
suggest margin structur sticki
 upper limit deal size would quantifi clearli
 outlook busi think opportun go forward robust
grow demand believ growth driver end
recent receiv request inform administr cap-lik program medicar part
 support find market-bas altern current buy bill paradigm
 remain confid us move away current rebat system mention
import lower pos price expect action administr end
year wolf comment line understand could news
y/e new part propos think best approach separ say
page
realli discuss payer potenti chang rebat structur done lot
intern assess discuss payer wolf comment payer drug compani
opposit end argument surpris
 contribut price volum expect go forward say price outlook
realli chang like industri look dynam januari moment time
believ take increas differ price volume fx
price say actual rang prior quarter year hover
minu plu low singl digit percent describ like price busi usual
 government program go net price commerci like follow suggest would like occur
would difficult maintain two differ price paradigm
 cerevel impact say impact result
start mention tafamidi formal nda file current quarter tanezumab recent
approv dacomitinib talazoparib lorlatinib glasdegib expect fda decis y/e
ad aa pneumococc conjug vaccin c-diff vaccin s-aureu vaccin
other expect approv half potenti blockbust
 tafamidi look rate diagnosi diseas slow fast abil
diagnos becom much easier use non-invas imag train burdensom
focu heavili next year
 big could tafamidi would say incred excit
 bavencio prospect renal cell given competitor data remain excit opportun
broad efficaci across subgroup believ inlyta remain gold standard tki
 dmd gene therapi program outlook believ good capsid begun dose patient
 educ physician rpoa tanezumab manag also confid
page fda osteonecrosi say remain confid rpoa major
type view benefit risk favor still
incom continu highli variabl partli mark market regul
 driver steadi growth innov medicin busi mention pipelin
demograph shift call xtandi io bavencio inlyta new oncolog nme launch y/e
although smaller new vaccin jak franchis opportun establish medicin
busi driver differ em
page
 like margin compress due lyrica loe answer talk
margin expans beyond wolf comment impli margin contract
 purpos new reorgan say busi differ growth
driver thu need restructur reflect busi unit wolf comment us seem
larg captur alreadi prior busi structur still clear us new reorgan
 happi current therapeut area footprint transact like cerevel occur futur
say believ current ta enough big categori overal small
enough number allow stay focus
 drive growth china call cv anti-infect portfolio favor
epidemiolog mention legaci product like lipitor norvasc growth also come
expand beyond big citi push region china describ
coloss remain untap opportun china
page
exhibit show compani report actual result vs estim consensu
exhibit pfizer result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit pfizer guidanc vs wr estim old new
page
oldnewoldnewrevenu bgross br bother incom /expenseapprox incomeapprox meffect tax dilut guidancewolf research estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement incom outstand total profit profit incom
page
exhibit wr balanc sheet cash flow statement
page
flow statement earn in-process sale impair restructur defer compens asset flow oper activ sale sale busi net invest flow invest activ chang short term repay long-term common dividend flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock cent par valu paid-in comprehens treasuri stock sharehold liabil sharehold
